{"transactions":[{"id":2707803,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":139289,"kind":"person","name":"Miles Darrin","position":1,"cik":"0001840076","reported_name":"Miles Darrin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2021-05-18T20:11:40.000Z","date":"2021-05-14","kind":"sale","acquired":false,"shares":3462,"price":55.41,"value":191829.42,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $55.40 to $55.47. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":7209,"source":{"system":"sec-edgar","filing":"0001439222-21-000041","document":"wf-form4_162136864414651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000041/wf-form4_162136864414651.xml","form_type":"4"}},{"id":2786066,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":139289,"kind":"person","name":"Miles Darrin","position":1,"cik":"0001840076","reported_name":"Miles Darrin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2021-03-16T20:14:21.000Z","date":"2021-03-05","kind":"sale","acquired":false,"shares":500,"price":48.58,"value":24290.0,"ownership":{"direct":true},"balance_after":10671,"source":{"system":"sec-edgar","filing":"0001439222-21-000031","document":"wf-form4_161592564145666.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000031/wf-form4_161592564145666.xml","form_type":"4"}},{"id":2786065,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":139289,"kind":"person","name":"Miles Darrin","position":1,"cik":"0001840076","reported_name":"Miles Darrin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2021-03-16T20:14:21.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":2200,"price":47.99,"value":105578.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 314 shares purchased through the Company's employee stock purchase plan."}],"balance_after":11171,"source":{"system":"sec-edgar","filing":"0001439222-21-000031","document":"wf-form4_161592564145666.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000031/wf-form4_161592564145666.xml","form_type":"4"}},{"id":2835716,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":139289,"kind":"person","name":"Miles Darrin","position":1,"cik":"0001840076","reported_name":"Miles Darrin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2021-02-24T21:14:07.000Z","date":"2021-02-22","kind":"exercise","acquired":false,"shares":725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on  February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on  February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":724,"derivative":{"underlying":"Common stock","underlying_shares":725},"source":{"system":"sec-edgar","filing":"0001439222-21-000023","document":"wf-form4_161420118102035.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000023/wf-form4_161420118102035.xml","form_type":"4"}},{"id":2835715,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":139289,"kind":"person","name":"Miles Darrin","position":1,"cik":"0001840076","reported_name":"Miles Darrin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2021-02-24T21:14:07.000Z","date":"2021-02-22","kind":"tax_withholding","acquired":false,"shares":215,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13057,"source":{"system":"sec-edgar","filing":"0001439222-21-000023","document":"wf-form4_161420118102035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000023/wf-form4_161420118102035.xml","form_type":"4"}},{"id":2835714,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":139289,"kind":"person","name":"Miles Darrin","position":1,"cik":"0001840076","reported_name":"Miles Darrin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2021-02-24T21:14:07.000Z","date":"2021-02-22","kind":"exercise","acquired":true,"shares":725,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13272,"source":{"system":"sec-edgar","filing":"0001439222-21-000023","document":"wf-form4_161420118102035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000023/wf-form4_161420118102035.xml","form_type":"4"}},{"id":2854268,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":139289,"kind":"person","name":"Miles Darrin","position":1,"cik":"0001840076","reported_name":"Miles Darrin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2021-02-17T21:14:43.000Z","date":"2021-02-16","kind":"exercise","acquired":false,"shares":922,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 16, 2018.  Beginning on February 16, 2019, the shares underlying the restricted stock units vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 16, 2018.  Beginning on February 16, 2019, the shares underlying the restricted stock units vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":922},"source":{"system":"sec-edgar","filing":"0001439222-21-000013","document":"wf-form4_161359645668070.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000013/wf-form4_161359645668070.xml","form_type":"4"}},{"id":2854267,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":139289,"kind":"person","name":"Miles Darrin","position":1,"cik":"0001840076","reported_name":"Miles Darrin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2021-02-17T21:14:43.000Z","date":"2021-02-14","kind":"exercise","acquired":false,"shares":8666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":17334,"derivative":{"underlying":"Common stock","underlying_shares":8666},"source":{"system":"sec-edgar","filing":"0001439222-21-000013","document":"wf-form4_161359645668070.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000013/wf-form4_161359645668070.xml","form_type":"4"}},{"id":2854266,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":139289,"kind":"person","name":"Miles Darrin","position":1,"cik":"0001840076","reported_name":"Miles Darrin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2021-02-17T21:14:43.000Z","date":"2021-02-16","kind":"tax_withholding","acquired":false,"shares":2916,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12547,"source":{"system":"sec-edgar","filing":"0001439222-21-000013","document":"wf-form4_161359645668070.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000013/wf-form4_161359645668070.xml","form_type":"4"}},{"id":2854265,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":139289,"kind":"person","name":"Miles Darrin","position":1,"cik":"0001840076","reported_name":"Miles Darrin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2021-02-17T21:14:43.000Z","date":"2021-02-16","kind":"exercise","acquired":true,"shares":922,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15463,"source":{"system":"sec-edgar","filing":"0001439222-21-000013","document":"wf-form4_161359645668070.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000013/wf-form4_161359645668070.xml","form_type":"4"}},{"id":2854264,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":139289,"kind":"person","name":"Miles Darrin","position":1,"cik":"0001840076","reported_name":"Miles Darrin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2021-02-17T21:14:43.000Z","date":"2021-02-14","kind":"exercise","acquired":true,"shares":8666,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14541,"source":{"system":"sec-edgar","filing":"0001439222-21-000013","document":"wf-form4_161359645668070.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000013/wf-form4_161359645668070.xml","form_type":"4"}},{"id":2863121,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":139289,"kind":"person","name":"Miles Darrin","position":1,"cik":"0001840076","reported_name":"Miles Darrin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2021-02-12T21:24:54.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":44000,"derivative":{"exercise_price":56.68,"expiration_date":"2031-02-10","underlying":"Common stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001439222-21-000008","document":"wf-form4_161316505175434.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000008/wf-form4_161316505175434.xml","form_type":"4"}},{"id":2863120,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":139289,"kind":"person","name":"Miles Darrin","position":1,"cik":"0001840076","reported_name":"Miles Darrin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2021-02-12T21:24:54.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":11000,"derivative":{"underlying":"Common stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001439222-21-000008","document":"wf-form4_161316505175434.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000008/wf-form4_161316505175434.xml","form_type":"4"}}]}